Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Total Non-Current Liabilities (2021 - 2026)

Zentalis Pharmaceuticals has reported Total Non-Current Liabilities over the past 6 years, most recently at $69.9 million for Q1 2026.

  • For Q1 2026, Total Non-Current Liabilities fell 20.66% year-over-year to $69.9 million; the TTM value through Mar 2026 reached $69.9 million, down 20.66%, while the annual FY2025 figure was $72.3 million, 21.71% down from the prior year.
  • Total Non-Current Liabilities for Q1 2026 was $69.9 million at Zentalis Pharmaceuticals, down from $72.3 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $112.5 million in Q4 2023 and troughed at $45.0 million in Q1 2022.
  • A 5-year average of $90.1 million and a median of $95.3 million in 2024 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 126.25% in 2023 and later decreased 28.98% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $102.7 million in 2022, then rose by 9.6% to $112.5 million in 2023, then dropped by 17.97% to $92.3 million in 2024, then decreased by 21.71% to $72.3 million in 2025, then decreased by 3.29% to $69.9 million in 2026.
  • Business Quant data shows Total Non-Current Liabilities for ZNTL at $69.9 million in Q1 2026, $72.3 million in Q4 2025, and $73.9 million in Q3 2025.